


RealRate

INC.


PHARMACEUTICAL 2017

REGENERON PHARMACEUTICALS Rank 18 of 313





REGENERON



The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 478% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 595% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	3,180,188
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,241,495
Liabilities, Non-Current	100,385
Other Assets	1,709,857
Other Compr. Net Income	-21,412
Other Expenses	733,987
Other Liabilities	1,182,341
Other Net Income	-926
Property and Equipment	2,083,421
Research and Development	2,052,295
Revenues	4,860,427
Selling, General and Administrative Expense	1,177,697

Output Variable	Value in 1000 USD
Assets	6,973,466
Liabilities	2,524,221
Expenses	3,963,979
Stockholders Equity	4,449,245
Net Income	895,522
Comprehensive Net Income	884,816
Economic Capital Ratio	179%

